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Background: Heavy alcohol use is associated with life-threatening complications including 
progressive liver disease. We aimed to analyze the impact of hepatitis C virus (HCV) infection 
on survival and liver-related death in alcohol-dependent patients.
Patients and methods: This is a longitudinal study in patients seeking treatment of alcohol 
abuse between 2000 and 2010. Information on alcohol use characteristics, alcoholic liver dis-
ease, and HCV infection were obtained at entry. Cumulated mortality and causes of death were 
ascertained through clinical records and death registry.
Results: A total of 819 patients (81.6% men) underwent ethanol detoxification; age was 44 (inter-
quartile range [IQR] 38–51) years; the duration of heavy alcohol use was 14 (IQR 6–24) years; 
and the alcohol consumption was 190 (IQR 120–250) g/day. The prevalence of HCV infection 
was 15.8%. There were 129 (16.9%) deaths during 5,117 persons-year (p-y) of follow-up (median 
follow-up 6.4 [IQR 4.3–9.2] years); 31 (24.6%) deaths were observed among the HCV-positive 
patients, and 98 (15.4%) deaths were observed among the HCV-negative patients. The mortality 
rate was significantly (P=0.03) higher among the HCV-positive patients (3.84×100 p-y; 95% 
confidence interval [CI]: 2.70, 5.46) than among the HCV-negative patients (2.27×100 p-y; 95% 
CI: 1.86, 2.77). Survival times for the HCV infected patients were 34% shorter (time ratio rela-
tive to HCV negative: 0.66; 95% CI: 0.51, 0.86). The main causes of death in the HCV-positive 
and -negative patients were liver-related mortality (48.4%) and neoplasia (22.4%), respectively. 
The liver-related mortality was significantly higher among the HCV-positive patients (adjusted 
sub-distribution hazard ratio [asHR] 3.65; 95% CI: 1.72, 7.78; P=0.001).
Conclusion: HCV infection compromises the survival of patients with alcohol abuse/depen-
dence. The new direct antiviral agents for the treatment of HCV infection may result in better 
clinical outcomes.
Keywords: hepatitis C virus, alcohol use disorder, survival, liver disease, mortality
Introduction
Harmful alcohol use is one of the leading causes of preventable death in Western 
countries, with excessive alcohol consumption as the third leading cause of premature 
death behind smoking and obesity. Mortality among individuals with heavy alcohol 
use is high due to several life-threatening complications related to excessive alcohol 
consumption, including progressive liver disease, cancer, nonnatural causes, and 
cardiovascular disease.
Among individuals with excessive alcohol consumption, 10–20% develop alco-
holic liver disease (ALD) in the course of chronic, heavy drinking and acute alcoholic 
hepatitis, the most florid manifestation of ALD will occur in some cases.1 ALD has 
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been reported to affect >2.5 million people in the USA and 
is the second most frequent indication for liver transplant in 
the USA and western Europe.2 Liangpunsakul3 summarized 
nationwide data on the clinical characteristics of alcoholic 
hepatitis in the USA, indicating that ~20% of patients have 
hepatitis C virus (HCV) infection and in-hospital mortality of 
episodes remains high. Furthermore, liver-related mortality 
increased globally from 2005 to 2015 and this trend largely 
reflects changes in major risk factors, such as excessive 
alcohol consumption and HCV infection.4
HCV infection affects 2–3% of the general population, 
disregarding marked regional differences.5 Mortality and 
disability-adjusted life-years due to HCV infection have 
increased, more than double since 1990.6 HCV infection has 
been recognized as a main risk factor for the progression of 
liver disease (ie, cirrhosis and hepatocellular cancer) and 
liver-related deaths worldwide, with nearly a quarter of cir-
rhosis deaths being attributed to this infection.4
The impact of HCV infection in individuals with exces-
sive alcohol consumption is relevant due to the fact that 
those who are infected are more likely to drink alcohol than 
someone without HCV.7 Excessive alcohol consumption 
may explain much of the poor prognostic outcomes and 
liver-related deaths in patients with HCV infection.8–12 The 
fraction of cirrhosis of the liver attributable to excessive 
alcohol consumption in patients with HCV infection is esti-
mated to be 36%13 and the alcohol attributable risk for liver 
transplantation and liver-related death associated with heavy 
alcohol use is estimated to be 67 and 68%, respectively.12
The molecular mechanisms underlying how alcohol exac-
erbates HCV infection and worsens liver injury remain to be 
elucidated. However, major components of the interactions 
between alcohol and HCV infection include the modulation 
of cytokine production, lipopolysaccharide-TLR4 signaling, 
and reactive oxygen species production.14,15
Hepatic oxidative stress and mitochondrial abnormalities 
are almost universally observed in patients with chronic HCV 
and appear to be an intrinsic component of the disease.14 
There is in vivo evidence of increased oxidative stress as 
the mechanism of synergy between alcohol and HCV in 
advanced liver damage, as the risk of developing oxidative 
stress during chronic HCV infection, is increased by heavy 
alcohol consumption and associated with increased fibrosis 
of the liver.16,17
We analyzed the role of chronic HCV infection on base-
line liver damage, long-term outcomes, and cause-specific 
mortality in a cohort of clinically well-characterized patients 
receiving treatment and care for alcohol dependence before 
the introduction of all-oral, direct acting antivirals (DAAs) 
for the treatment of HCV infection. In the context of chang-
ing the treatment paradigm of HCV infection,18 we theorize 
that the burden of liver disease in alcohol-dependent patients 
with HCV infection may result in an excess mortality that 
could be reduced in the era of new DAAs.
Patients and methods
Study population
This longitudinal study was carried out in a cohort of patients 
admitted for the treatment of alcohol dependence between 
January 2000 and December 2010 in the following two hospital 
units in metropolitan Barcelona, Spain: Hospital Universi-
tari de Bellvitge in L’Hospitalet de Llobregat and Hospital 
Universitari Germans Trias i Pujol in Badalona. All patients 
provided written informed consent. The study was conducted 
in compliance with the ethical standards for medical research 
and principles of good clinical practice in accordance with the 
World Medical Association’s Declaration of Helsinki, follow-
ing Spanish Law 14/2007 on Biomedical Research. The study 
was approved by the Ethics Committees of the Hospital Uni-
versitari de Bellvitge and the Hospital Universitari  Germans 
Trias i Pujol.
A flow chart of admission to the study is shown in 
 Figure 1. After applying exclusion criteria, the study popula-
tion included 819 patients.
Clinical assessment
Patients were referred to inpatient detoxification by primary 
care physicians and specialists in addiction medicine at 
community-based centers. All patients received the diagno-
sis of alcohol dependence according to the Diagnostic and 
Statistical Manual of Mental Disorders, 4th edition (DSM-
IV),19 and the main criteria for referrals included severity of 
alcohol dependence, medical comorbidity, and the risk of 
alcohol withdrawal, among others.
On the day of admission, patients underwent an interview 
that included questions on the history of alcohol consumption 
and the use of other substances. History of alcohol consump-
tion included age when started drinking, duration of alcohol 
abuse, and quantity of alcohol consumption at admission. 
Alcohol consumption was quantified in grams per day (10 g 
=1 standard drink unit).
In all cases, blood samples were drawn the day after 
admission for liver function tests including aspartate amino-
transferase (AST), alanine aminotransferase (ALT), gamma 
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Serum samples were tested for HCV and human immu-
nodeficiency virus (HIV) infections. HCV screening was 
based on enzyme immunoassay (EIA) analysis and positive 
tests confirmed by real-time polymerase chain reaction (HCV 
RNA). Patients with a positive HCV RNA test were consid-
ered as having ongoing HCV infection. For the purposes of 
this study, patients with HIV infection were excluded.
ALD was diagnosed if patients met two or more of the 
following criteria:20,21 AST elevation 74–300 U/L, AST/ALT 
ratio ≥2, and total bilirubin >1.2 mg/dL. Pharmacological 
treatment during admission included the administration of 
benzodiazepines, vitamin B complex, and other medications 
depending on medical comorbidity. On average, the length of 
stay was 6 days and, at discharge, patients were transferred to 
the primary care centers and recommended follow-up visits 
at an outpatient clinic.
Mortality and causes of death
Clinical outcomes and date and cause of death were ascer-
tained through the review of clinical charts and cross-
checking with the mortality register through June 30, 2014. 
Causes of death were coded according to the International 
Classification of Diseases Version 10 (ICD-10)22 and classi-
fied into the following five categories:
1. Liver related, including ALD, viral hepatitis, and hepato-
cellular carcinoma: B15–B19, C22, K65, K70–K77, and 
I85;
2. Cardiovascular: I00–I84 and I86–I99;
3. Malignant neoplasm, excluding hepatocellular carci-
noma: C00–C21, C23–C97, D00–D09, and D37–D48;
4. Nonnatural (violence, accidents, and overdose): F10–
F19, V00–V99, W00–W99, X00–X99, and Y00–Y36; 
and
5. Others: codes not mentioned in prior causes.
Statistical analyses
Differences between the HCV-negative and the HCV-positive 
patients (ie, socio-demographics, alcohol use, liver function, 
and ALD) were assessed through the nonparametric Mann–
Whitney test for continuous variables and the Chi-square test 
for categorical variables.
In all-cause mortality and liver-related mortality analyses, 
we used age as the time scale allowing the best possible con-
trol of a powerful predictor of mortality. We only considered 
person-time and events between the ages of 35 and 65 years, 
anchoring the time origin at age 35 years to prevent sparse 
events from having undue influence on results. We used 
late entry methods, left-truncating data at the time of entry 
Figure 1 Selection of study population.
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and appropriately aligning person-time on the age scale, to 
accommodate individuals who entered the study after the age 
of 35 years. We administratively censored events and person-
time after June 30, 2014. To quantify the putative reduction in 
survival times due to infection with HCV, we fit conventional 
generalized gamma models whereby infection with HCV 
modified the location parameters. The antilog of the differ-
ence of the location parameters estimates the ratios of the 
percentiles of the HCV positive to those of HCV negative.23
For liver-related mortality, all unknown causes of death 
were assumed to be nonliver related, as most of them (90.9%) 
were observed among the HCV-negative patients. We used the 
Kaplan–Meier method to estimate the cumulative incidence 
of death from any cause and Cox proportional hazards’ mod-
els to calculate mortality hazard ratios (HRs). Proportional 
hazards’ models on the sub-distribution hazard were used to 
estimate sub-distribution HRs (sHRs) for liver-related mor-
tality, treating nonliver-related deaths as competing events. 
Multivariable models were adjusted for sex and ALD.
A set of sensitivity analyses was undertaken. Analyses 
were repeated using years from admission to treatment as 
the time scale, considering four different approaches to deal 
with unknown causes of death in liver-related mortality 
analyses (considering all unknown causes of death as another 
competing event, assuming all unknown causes of death to 
be liver related, assuming all unknown causes of death to be 
nonliver related, and imputing all unknown causes of death 
using multiple imputation by chained equations).
All statistical analyses were performed using the Stata soft-
ware (Version 14.0; StataCorp LP., College Station, TX, USA).
Results
Characteristics of the study population
Eight hundred nineteen patients (81.6% men) were included 
in the study. The median age at admission was 44 years 
(interquartile range [IQR] 38–51 years), the median duration 
of heavy alcohol use was 14 years (IQR 6–24 years), and the 
median alcohol consumption at admission was 190 g/day (IQR 
120–250 g/day). A total of 129 (15.8%) patients had HCV 
infection, and 14.2% of patients met the criteria for ALD.
Table 1 provides the baseline characteristics of patients 
according to HCV status at admission. Patients with HCV 
Table 1 Baseline characteristics of 819 patients admitted for the treatment of alcohol dependence and HCV status
Variables HCV negative (N=690), n (%) HCV positive (N=129), n (%) P-value
Men 559 (81.0) 109 (84.5) 0.35
Age (years), median (IQR) 45 (38–52) 42 (38–46) 0.001
Alcohol and substance use
Duration of alcohol dependence (years), median (IQR) 10 (4.1–20) 10 (4.5–21.5) 0.88












Liver-related parameters, median (IQR)
ALT (U/L) (n=796) 33 (20–55.2) 57.6 (32.4–90.6) <0.001
AST (U/L) (n=796) 36 (22.2–70.2) 59.4 (33.6–96) <0.001
GGT (U/L) (n=791) 108.6 (45.6–280) 162.6 (85.8–323.4) 0.003
Alkaline phosphatase (U/L) (n=765) 73 (60–94.2) 72 (58.5–96) 0.59












Hematology and biochemistry, median (IQR)
Leukocytes (×109/L) (n=805) 6.7 (5.5–8.3) 6.4 (5.1–8.0) 0.10
Hemoglobin (g/dL) (n=805) 14.1 (13–15.1) 13.8 (13–15.2) 0.43
Platelets (×109/L) (n=805) 199 (153–251) 183 (123–241) 0.02
Creatinine (mg/dL) (n=800) 0.8 (0.7–0.9) 0.8 (0.7–0.9) 0.63
Glucose (mg/dL) (n=791) 93.7 (86.5–104.5) 92 (83–100.9) 0.04
Albumin (g/L) (n=794) 40 (37–42) 39 (36–41) 0.02
Total cholesterol (mg/dL) (n=797) 191.4 (164.0–225.1) 164.1 (139.6–189.5) <0.001
Triglycerides (mg/dL) (n=769) 106.3 (79–159.4) 88.6 (70–124.0) <0.001
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infection were more likely to be younger and current cocaine 
users than HCV-negative patients. Platelet count, total serum 
cholesterol, triglycerides, glucose, and albumin levels were 
significantly different between the HCV-positive and -nega-
tive patients. Regarding liver function tests, serum levels 
of AST, ALT, and GGT were substantially higher in HCV-
infected patients.
Overall and cause-specific mortality
Using the analytical sample as of June 30, 2014, there were 
129 (16.9%) deaths during 5,117 persons-year of follow-up 
(median follow-up 6.4 years [IQR 4.3–9.2 years]); 31 (24.6%) 
deaths were observed among the HCV-positive patients and 
98 (15.4%) deaths were observed among the HCV-negative 
patients. The overall mortality rate was 2.52 (95% confidence 
interval [CI]: 2.12, 2.99) per 100 person-years: 3.84 (95% 
CI: 2.70, 5.46) in HCV-positive patients and 2.27 (95% CI: 
1.86, 2.77) in HCV-negative patients.
The crude HR comparing HCV-positive and HCV-
negative patients was 2.00 (95% CI: 1.32, 3.02), attenuated 
to 1.88 (95% CI: 1.24, 2.84) after controlling for sex and 
ALD. Figure 2 shows the survival estimates in HCV-negative 
and HCV-positive patients. The conventional generalized 
gamma model provided a reasonable fit to the nonparametric 
estimates and indicated a statistically significant 34% reduc-
tion in survival times among the HCV-positive relative to the 
HCV-negative patients (time ratio: 0.66; 95% CI: 0.51, 0.86).
Overall, the main cause of death was liver-related mor-
tality (25.6%), followed by neoplasia (20.2%), nonnatural 
(11.6%), and cardiovascular disease (9.3%). Figure 3 shows 
cause-specific mortality according to HCV status. Interest-
ingly, liver-related death accounted for 48.4% of cause-
specific mortality in HCV-positive patients and 18.4% in 
HCV-negative patients. Cancer was the main cause of death 
in HCV-negative patients. The mortality rate due to liver-
related deaths was higher in HCV-positive patients than in 
HCV-negative patients (sHR 4.25; 95% CI: 2.07, 8.77), a 
difference that was significant after adjusting for sex and ALD 
(adjusted sHR [asHR] 3.65; 95% CI: 1.72, 7.78; P=0.001). 
Figure 4 shows the cumulative incidence of liver-related death 
in HCV-negative and HCV-positive patients admitted for the 
treatment of alcohol dependence.
Figure 2 Survival estimates in HCV-negative and HCV-positive patients with alcohol use disorders according to Kaplan–Meier and generalized gamma models.
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HR, hazard ratio.
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Figure 3 Cause-specific mortality in a cohort of 819 alcohol-dependent patients with and without HCV infection in metropolitan Barcelona, Spain. 





































Figure 4 Cumulative incidence of liver-related death in HCV-negative and HCV-positive patients admitted to alcohol detoxification.
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Performing procedures of sensitivity analyses mentioned 
earlier yielded results consistent with those of the main 
analysis (data not shown).
Discussion
In this longitudinal study with long-term follow-up (median 
6 years), HCV-positive patients had almost a two-fold 
increase in mortality rate with respect to patients without 
infection, thus indicating the negative impact of HCV infec-
tion in a population with high prevalence of infection.24 Alco-
hol and HCV infection are the leading causes of end-stage 
liver disease worldwide and the most common indications 
for liver transplant in the USA and Europe.2
An interesting finding from this clinical cohort is that 
HCV infection significantly reduces the survival of alcohol-
dependent patients with respect to those without infection. 
The burden of years of life lost is high if we consider that 
the median age of patients seeking treatment of the disorder 
is 44 years. To the best of our knowledge, this has not been 
reported previously in a series of alcohol-dependent patients.
The majority of studies analyzing the mortality of 
alcohol-dependent patients with HCV infection have been 
linked to electronic health records.12,25 In a study by Grebely 
et al,26 HCV infection in general population had no impact on 
all-cause mortality but HCV infection itself was associated 
with liver-related death. In a diverse population of substance-
dependent patients admitted to detoxification, Accurso et 
al,27 also indicates that HCV infection is not a risk factor for 
all-cause mortality.
A recent study reported that up to 30% of patients with 
HCV infection may experience excessive alcohol consump-
tion, and when both diseases occur concurrently, the liver-
related mortality is six times higher than that of HCV-negative 
patients with liver-related complications.12
Interestingly, in this study, the excess of liver-related 
mortality was explained by the impact of HCV infection; 
alcohol-dependent patients with HCV infection are three 
times more likely to die from liver-related disease than 
alcohol-dependent patients without HCV infection, which 
suggest that early assessment of liver damage and treatment 
of both alcohol dependence and HCV infection may reduce 
the excess of liver-related mortality in this population. In 
the context of a high risk of liver-related comorbidity (ie, 
ALD, acute alcoholic hepatitis, and cirrhosis) due to exces-
sive alcohol consumption, HCV infection triples the risk of 
liver-related death. All of this reveals that it is necessary to 
reduce the impact of HCV infection in a population that does 
not have easy access to conventional health care.28 Changes 
in the treatment of HCV infection after the introduction of 
DAAs could facilitate the sustained viral response of patients, 
improving the survival of patients after detoxification from 
alcohol. Studies have shown that excessive alcohol con-
sumption and other substance use disorders do not usually 
compromise adherence to HCV treatment29,30 and that per-
sons engaged in treatment who have achieved sobriety have 
HCV treatment outcomes similar to those without histories 
of associated substance use.31,32
Despite the great impact of HCV infection in patients 
with excessive alcohol consumption, a recent systematic 
review of medical comorbidity in patients with alcohol use 
disorders did not include the association of HCV infection 
but did include heavy alcohol use with other infections, 
such as HIV and tuberculosis.33 Conversely, the current 
guidelines from the American Association for the Study 
of Liver Disease, the European Association for the Study 
of the Liver, and the World Health Organization already 
recommend treatment for HCV infection in people with 
substance use disorder.18,34–36
This study has several limitations. First, our analysis did 
not include changes in alcohol consumption over time. Absti-
nence from alcohol is the main goal in patients with alcohol 
dependence; in this sense, having information on remission 
and relapse of excessive alcohol use over time could better 
facilitate the interpretation of survival as a function of suc-
ceeding after detoxification from alcohol. Second, patients 
were primarily admitted to treatment because of the severity 
of alcohol dependence; therefore, our study did not include 
individuals with less severe patterns of alcohol consumption, 
limiting the generalization of results. Third, there may be a 
risk of misclassifying causes of death due to the limitations of 
ICD-10, which codifies death as a single cause according to 
a set of rules to extract maximum information. The strengths 
of this study are related to the well-characterized cohort that 
includes a large number of patient-years of observation, the 
analysis of causes of death and competing risks that are not 
usually available when using linked health records, and the 
sensitivity analysis suggesting that unknown causes of death 
have not threatened the results.
Conclusion
Alcohol abuse/dependence and HCV infection are conditions 
that may have clinical consequences when interacting. In 
summary, hepatitis C worsens the prognosis of liver disease 
and compromises the survival of alcohol-dependent patients. 
In this sense, treatment and care of HCV infection may result 
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